[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.74.94. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
April 1985

Stanozolol in the Treatment of Pityriasis Rubra Pilaris

Author Affiliations

From the Departments of Dermatology, Wayne State University School of Medicine, Detroit, and Veterans Administration Medical Center, Allen Park, Michigan.

Arch Dermatol. 1985;121(4):546-548. doi:10.1001/archderm.1985.01660040130028
Abstract

Pityriasis rubra pilaris (PRP) is a rare papulosquamous disease characterized by erythroderma, acuminate follicular papules, with so-called islands of sparing, follicular hyperkeratosis, palmoplantar keratoderma and occasional lymphadenopathy, hair loss, mucosal lesions (white or blue lines or erythematous lesions transversed by white streaks), and eye lesions (corneal opacities, conjunctivitis, keratitis). Pityriasis rubra pilaris can be widespread and very distressing to the patient, because limitation of motion and painful fissuring of palmar and plantar surfaces can occur. Among the many treatment modalities that have been used are vitamin A alone1 or in combination with vitamin E,2 topical aminonicotinamide,3 azathioprine,4 methotrexate,5 isotretinoin,6 etretinate,7 PUVA,7 and systemic steroids.8 Anecdotal reports indicate that ascorbic acid or penicillin might also be of benefit. Lamar and Gaethe,8 in their review of PRP, documented the effects of old remedies, such as arsenic, foreign protein injections, pilocarpine, pituitary extract, carotene,

First Page Preview View Large
First page PDF preview
First page PDF preview
×